戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nsitivity, specificity, cost-efficiency, and patient adherence.
2 estyle factors, therapeutic inertia and poor patient adherence.
3 and extended-release activity to combat poor patient adherence.
4  in the need for frequent dosing and reduced patient adherence.
5 rtening dose escalation regimens to increase patient adherence.
6 ft rejection with the potential for improved patient adherence.
7  resistance, systemic side effects, and poor patient adherence.
8 e of reducing ISRs and potentially enhancing patient adherence.
9 2; P = .028) were negatively associated with patient adherence.
10  pill burdens and costs as well as improving patient adherence.
11  ejection fraction and the conundrum of poor patient adherence.
12 % CI, 1.11-1.41) were associated with better patient adherence.
13 rrent three-to-five-year regimens, enhancing patient adherence.
14 depot systems are being developed to improve patient adherence.
15 erapies can prevent resistance regardless of patient adherence.
16  that have yet to be assessed in relation to patient adherence.
17 ch program ultimately depends on quality and patient adherence.
18  there is room to expand services to improve patient adherence.
19 0 of 4), patient-reported outcomes (0 of 3), patient adherence (1 of 2), or clinical outcome measures
20 strategies to improve provider practices and patient adherence across health sectors are urgently nee
21                Multivariable regressions for patients' adherence adjusting for race, symptom measures
22 , but its efficacy is hampered by incomplete patient adherence and ART-resistant variants.
23 present actionable opportunities to optimize patient adherence and clinical outcomes.
24 ulosis treatment could significantly improve patient adherence and decrease the development of drug r
25 s reveals that even in conditions of perfect patient adherence and drug penetration a substantial lev
26 quent intratumoral injections, which hinders patient adherence and increases clinical burden.
27 e long treatment duration (resulting in poor patient adherence and loss of patients to follow-up), co
28 ent discussion of the costs of care improves patient adherence and outcomes requires further study.
29         Awareness of factors related to poor patient adherence and persistence in nAMD could help ide
30                              Addressing both patient adherence and provider intensification simultane
31 d the prevalence of and relationship between patient adherence and provider treatment intensification
32 ities and socioeconomic barriers often limit patient adherence and self-management with hemodialysis.
33 ve shown that there is a correlation between patient adherence and treatment outcomes.
34 ion and mental health, in turn, could affect patients' adherence and the ability to make adaptive lif
35 ght be reduced through improvements in care, patient adherence, and communication.
36 ent dosing frequency could result in greater patient adherence, and thus, improved disease management
37               Strategies that foster greater patient adherence are also identified.
38          Targeted interventions facilitating patient adherence are needed and have the potential to i
39      Additional effort is required to ensure patient adherence, as well as additional support to clin
40 therapies in the 30 days after discharge and patient adherence at 12 months after discharge, adjustin
41  combinations, incorporating factors such as patient adherence behavior.
42 mately 40 million people worldwide, with low patient adherence being the primary challenge for mainta
43 us (SC) injection due to its convenience and patient adherence benefits.
44                                              Patient adherence contributed to 44% of patients with mi
45 in a shared decision-making process based on patients' adherence, diabetic macular edema status, and
46                     Electronic monitoring of patient adherence documented that a sizable number of pa
47 of antiretroviral therapy (ART) include poor patient adherence, drug toxicities, viral resistance, an
48 icrobial sanctuaries and reservoirs, and low patient adherence due to drug-related toxicities and ext
49 ims and modalities of management; suboptimal patient adherence, even to demonstrably effective therap
50 cine-based home management program (THMP) on patient adherence, hospital readmissions, and quality of
51 n contact and satisfaction, quality of life, patient adherence, hospitalizations, and mortality.
52 ion discrepancies, number of medications and patient adherence identified in this study.
53 nd psychological patient outcomes, increases patient adherence, improves health care quality and safe
54 is necessary to explore which factors affect patient adherence in order to improve clinical practice
55 esearch has been done on the problem of poor patient adherence in pediatric chronic illnesses, the pr
56                                              Patient adherence is critical in evaluating the effectiv
57  conceptual framework of factors that affect patient adherence is presented.
58 ntraocular pressure (IOP) is limited by poor patient adherence, low bioavailability of drug and the p
59 urgical and endoscopic interventions or high patient adherence, making it challenging for patients wi
60 barrier to resistance combined with improved patient adherence may mitigate TDR increases by reducing
61                                     Improved patient adherence may reduce rate of recurrent VTE.
62 predecessors as well as to other widely-used patient adherence measures, across countries and patholo
63 oring (n = 256, 60.8%), and errors involving patient adherence (n = 89, 21.1%) also were common.
64 tributed, by deduction, to difficulties with patient adherence or, to a lesser degree, to metabolic a
65 comparable outcomes and equivalent levels of patient adherence, patient satisfaction, and health care
66 influenced by genetic barrier, drug potency, patient adherence, pharmacological barrier, viral fitnes
67 ASRI ratings were moderately correlated with patient adherence (pharmacy), supporting the concurrent
68                                  In adherent patients (adherence quartiles 2-4), the median time to e
69 h technologies have the potential to improve patient adherence, reduce adverse effects, and prolong t
70                                              Patients adherence seems to influence the prognostic val
71                                              Patients' adherence seems to have an impact on the predi
72 ward improving statin prescription rates and patient adherence should also be priorities for future r
73 o assess current patterns of prescribing and patient adherence, target programs to address problem ar
74 ed dosing histories provide detailed data on patient adherence that can be used for efficient medicat
75                                              Patient adherence, the level of asthma self-management s
76 roportion of patients prescribed primaquine, patient adherence to a full course of primaquine, and ef
77 d to determine the best methods of enhancing patient adherence to a screening program.
78 ceptor-positive (HR-positive) breast cancer, patient adherence to AET and continuation of treatment a
79 gitudinal, prospective study aimed to assess patient adherence to and acceptance of once-daily tacrol
80                                              Patient adherence to antibiotic prophylaxis did not alte
81                                              Patient adherence to antihypertensive medications is not
82 re providers in facilitating improvements in patient adherence to antihypertensive medications, to pr
83 tions, to provide a framework for addressing patient adherence to antihypertensive therapy, and to pr
84 role of the healthcare provider in improving patient adherence to antihypertensive therapy.
85 rove the delivery of behavioral services and patient adherence to behavioral recommendations.
86 der and racial/ethnic gaps in the use of and patient adherence to beta-blockers, angiotensin-converti
87 ased activities were associated with greater patient adherence to dabigatran.
88 t its efficacy is highly dependent on strict patient adherence to daily dosing regimen.
89                   This cohort study assesses patient adherence to diabetes screening using hemoglobin
90 e due to pharmacologic factors or suboptimal patient adherence to drug therapy.
91            For many chronic ocular diseases, patient adherence to eye drop dosing regimens and the ne
92 ioavailability to target tissues and lack of patient adherence to frequent dosing regimens.
93 while off-target side effects lead to dismal patient adherence to lifelong drug regimens.
94                       While recognizing that patient adherence to lifestyle changes is the basis for
95  the creation of reminder systems to improve patient adherence to medical recommendations.
96 y systems are promising platforms to improve patient adherence to medication by delivering drugs over
97 tation and what parameters are influenced by patient adherence to nutritional care.
98                                              Patient adherence to prescribed antiviral therapy in hum
99 lance model that was then applied to examine patient adherence to prescribed LCD treatment programs.
100  properly managed, largely due to inadequate patient adherence to prescribed treatment regimens.
101 risk factors may improve risk assessment and patient adherence to prevention guidelines.
102 s are required to self-manage their care but patient adherence to prevention strategies is a signific
103 led brochure is an effective way to increase patient adherence to primary care physician referral for
104 ded to increase both healthcare provider and patient adherence to recommendations for retesting men a
105 ysician implementation of and secondarily on patient adherence to recommended survivorship care, amon
106 n effects on physician implementation of and patient adherence to recommended survivorship care.
107 is of hair as a clinical tool for monitoring patient adherence to the antiretroviral maraviroc (MVC).
108                Analyses were irrespective of patient adherence to the DPWG guidelines.
109 oma exist, their efficacy is limited by poor patient adherence to the prescribed eye drop regimen.
110 issue concentrations and will require strict patient adherence to the regimen.
111 duced dosing frequencies, thereby amplifying patient adherence to therapeutic regimens.
112  We use this model to study the influence of patient adherence to therapy and of common retreatment r
113 ately, inconvenient regimens leading to poor patient adherence to therapy, and the increasing frequen
114                                              Patient adherence to these medications is required for b
115       Before considering systemic treatment, patient adherence to topical treatment including skin ca
116 ore effective than medical care in promoting patient adherence to treatment and patient satisfaction.
117                  Concurrent chemotherapy and patient adherence to treatment were significant mediator
118                                              Patients' adherence to antihypertensive drug regimens is
119 emples, and orbits and may negatively affect patients' adherence to highly active antiretroviral ther
120 gs for stroke/TIA prevention did not address patients' adherence to medication or medication targets,
121 y and daily routine were found to impact the patients' adherence to medications.
122 ients for their risk of abuse and to monitor patients' adherence to prescribed treatments.
123 inical interactions, especially by improving patients' adherence to recommended therapies.
124 ches to off-loading similarly depends on the patients' adherence to the effectiveness of pressure rel
125 tinopathy (DR) screening programs depends on patients' adherence to the timetable of follow-up eye ca
126 hnique (PL-BCT) intervention on hemodialysis patients' adherence to their complex therapeutic regimen
127     Prior studies, however, did not consider patients' adherence to their regimens or HAART effective
128  detection and prompt treatment may increase patients' adherence to tyrosine kinase inhibitor therapy
129                                      In some patients, adherence to MS treatment may be less than opt
130 orders, improved documentation, and improved patient adherence, to date, no systematic reviews have b
131 stics were found to be inadequate to predict patients' adherence trajectories.
132                                              Patient adherence was associated with clinician's data u
133                                              Patient adherence was tracked with reasons for missed se
134              For evaluation of premenopausal patients, adherence was 63% (overmanagement, 30%) and of
135                                     Among 90 patients, adherence was 89.7% +/- 13.7% overall and 80.9
136 n-group differences in medication changes or patient adherence were identified.
137 one strength offers the potential to improve patient adherence which further might increase clinical
138                               One barrier to patient adherence with chronic topical glaucoma treatmen
139           Interventions focused on improving patient adherence with prescribed regimens and monitorin
140                                              Patients' adherence with posttransplant immunosuppressio
141                                              Patients' adherence with the antipsychotic regimen was c

 
Page Top